The REDUCE LAP-HF II study is being conducted to evaluate the clinical efficacy and safety of the InterAtrial Shunt Device (IASD®) System II for patients with left ventricular ejection fraction > 40% and elevated left atrial pressure who remain symptomatic despite appropriate medical management. The IASD System II is the first device therapy designed for heart failure with preserved ejection fraction.